Merck KGaA is a science and technology company operating across three business segments: Healthcare, Life Science, and Electronics. In Healthcare, the company develops pharmaceuticals and vaccines for oncology, neurology and immunology, fertility, endocrinology, and general medicine. The Life Science segment provides process solutions, advanced solutions, and discovery solutions to support research and development in laboratories. The Electronics segment supplies materials, equipment, and services for the semiconductor industry, including thin films, optronics, formulations, metrology and inspection, delivery systems, and specialty gases. In the United States and Canada, the company's subsidiaries operate under the EMD brand.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - General Homepage merckgroup.com
Sector Healthcare IR page merckgroup.com/en/investors
Tags
pharmaceuticals, oncology, neurology, immunology, fertility, endocrinology, life science tools, research services, semiconductor materials, thin films, specialty gases, metrology, EMD, AIDDISON, Intermolecular
Press page —

Metrics

Valuation  
Market cap € 65.782B
Market cap (USD) $ 72.702B
P/E 27.69
PEG —
P/BV 2.17
P/S 3.12
P/OCF 14.25
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.9%
ROI 9.1%
ROIC 12.6%
Profit margin 12.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -7.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 21.102B 21.156B 20.993B 19.687B 17.534B 16.152B 14.836B 15.327B 15.024B 12.845B 11.292B 10.7B 10.741B 9.906B 8.929B —
Net profit 2.615B 2.786B 2.834B 3.055B 1.987B 1.32B 3.374B 2.605B 1.633B 1.124B 1.165B 1.209B 579M 629M 1.194B 230.2M

Figure FY 2025 FY 2024 FY 2023 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 122.6 139.9 144.1 227 140.35 105.35 89.98 89.75 99.15 89.57 78.42 65.13 77.03 77.03 59.85 65.16
Price performance 12m -0.12 -0.03 -0.2 0.62 0.33 0.17 0 -0.09 0.11 0.14 0.2 -0.15 0 0.29 -0.08 —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Merck opens €300 million Daejeon bioprocessing center Bull 2 Bear 0 Product/operations

digi·access - Improve accessibility

Optimize the website for better readability and user experience.

F2 to open

The page is reloaded when used

English

Deutsch

English

Español

Français

Italiano

Nederlands

Polski

Čeština

Türkiye

Dansk

Svenska

Suomi

Português

Norsk

Slovenčina

Magyar

Tiếng Việt

Adjustments for accessibility

Choose your settings

Visually impaired people Support for people with poor eyesight

Off

On

Reading texts aloud Assistance for users who have problems reading online texts

Off

On

Cognitive Restrictions Provides assistance to read and recognise important elements

Off

On

Epileptics Animations are deactivated and dangerous colour combinations reduced

Off

On

ADHD settings Distractions are reduced and a clear focus is set

Off

On

Blind People The screen reader can recognise contents of the web page

Off

On

Motor impaired people The website can be navigated via keyboard

Off

On

Reset all settings Your adjustments for accessibility are set back to the standard settings

Reset

Individual adjustments

Font size

Reset

Line spacing

Reset

Content size

Reset

Word spacing

Reset

Black / white Hide images Highlighting Mouse Simple font

Stop animations Mute sound Reading Mask Magnifier

Extended adjustments

Character spacing

Reset

Highlight link Large pointer

Virtual keyboard Saturation Contrast Video

Background colour

Reset

Text colour

Reset

Link colour

Reset

Title colour

Reset

Close

Reset

Hide widget

Barrierefreie Webseite mit digi·access GmbH, Version 3.47.12 Copyright © 2026

Hide digi·smartPlugin?

Once hidden, it will only be available again by deleting your browser data. Do you want to continue?

Cancel Confirm

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go Cancel

Internet Explorer is not supported

You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser

Accept

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.

OK Cancel

{"analytics":"targeting"}

Disclaimer Image

Disclaimer

Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

Accept

Skip to main content

Select your Market

Global

Global

{{ cartLength }}

DE Change language to German

EN

You are currently browsing content in English

Our share price

€150.9

0.40%

CAREERS

Show All Results

0 matching results. Select 'Show All Results' link to see additional results

Discover with us

2025 Annual Report 2025 Annual Report 2025 Annual Report 2025 Annual Report

FY 2025 Online Report

Annual Report

AI Assistant AI Assistant AI Assistant AI Assistant

Chat with our AI assistant

Get Instant Answers

Build what's next with us. Build what's next with us. Build what's next with us. Build what's next with us.

Build what's next with us.

Explore Careers

Show All Results

0 matching results. Select 'Show All Results' link to see additional results

Discover with us

2025 Annual Report 2025 Annual Report 2025 Annual Report 2025 Annual Report

FY 2025 Online Report

Annual Report

AI Assistant AI Assistant AI Assistant AI Assistant

Chat with our AI assistant

Get Instant Answers

Build what's next with us. Build what's next with us. Build what's next with us. Build what's next with us.

Build what's next with us.

Explore Careers

  • Company

Company

About us

Sustainability

Expertise

Life Science

Healthcare

Electronics

Research

Research

Grants & Awards

Science Space

News & Media

Investors

Investor Relations

Global

DE Change language to German EN You are currently browsing content in English

Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea

Merck opened a €300 million Daejeon center, expanding regional capacity and access to critical bioprocessing materials.

Subscribe

Share Icons revealed to the left

29 Oct 2026 | Darmstadt, Germany

  • Merck’s largest life science investment in Asia-Pacific to date expands regional manufacturing capacity

  • Integrated digital systems support automated data capture and end-to-end batch traceability

  • Advances Merck’s in-region-for-region strategy, bringing critical products closer to customers across Asia-Pacific

  • State-of-the-art facility designed to eliminate on-site fossil-fuel use and improve energy and water efficiency

Merck, a leading science and technology company, today opened its new Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea. The center represents an investment of more than €300 million, the company’s largest Life Science investment in Asia-Pacific to date.

The 44,500-square-meter site expands the Merck’s regional manufacturing capacity for critical materials and solutions used in the development and production of biologic medicines. It gives biopharmaceutical manufacturers across Asia-Pacific closer access to the materials and solutions needed to develop and produce biologic medicines.

"Reliable access to critical materials is essential at every stage of biologics manufacturing,” said Jean-Charles Wirth, Member of the Executive Board of Merck, and CEO Life Science. “Daejeon brings advanced production closer to biopharma manufacturers across Asia-Pacific, giving them greater supply confidence, as they move from development to commercial scale. The center adds the regional capacity customers need and delivers the quality and consistency they expect from Merck.”

From Daejeon, Merck will supply bioprocessing products used from early process development through commercial-scale manufacturing. These include cell culture media in dry powder and liquid formats, including pre-GMP small-scale custom products through imMEDIAte ADVANTAGE®, process liquids and ready-to-use cleaning-in-place solutions; and single-use sterile sampling solutions based on the NovaSeptum® Sterile Sampling System. Together, they help customers accelerate development, scale production, maintain controlled manufacturing environments and reduce contamination risk. Cell culture media and process liquids will use animal-component-free raw materials and be manufactured to consistent global quality standards.

“The completion of Merck’s Asia-Pacific Bioprocessing Production Center, a world-leading bioscience company, marks a historic turning point in Daejeon’s rise as a global bio hub—not just for Korea, but for the world." said Tae-Jeong Heo, Mayor of Daejeon. “We will provide our full support to ensure that Merck’s foundational technologies at the Daedeok Innopolis and the capabilities of the local community can be brought together seamlessly. We will focus the city’s resources on building a world-class global bio ecosystem through close collaboration among industry, academia, research institutions, and hospitals.”

The center’s integrated digital ecosystem is designed to support automated data capture and end-to-end batch traceability, increasing process transparency and supporting quality management and regulatory compliance.

The facility is designed to eliminate the use of fossil fuels on-site while increasing energy and water efficiency through the use of solar power, a heat-pump system, energy recovery in air handling units, and rainwater reuse.

The Daejeon center is a key part of Merck’s in-region-for-region strategy. It builds on recent investments across the company’s global network, including BioReliance® drug product testing in Darmstadt, Germany, and filtration manufacturing in Blarney, Ireland. Across this network, Merck is bringing critical products and services closer to customers while applying consistent global quality standards.

Downloads

  • Merck-Opens-Asia-Pacific-Bioprocessing-Production-Center-in-Daejeon-EN.pdf

pdf (105.4 kB)

  • daejeon-opening-merck.jpg

image/jpeg (578.6 kB)

Pimicotinib MANEUVER 2-year data Bull 5 Bear 0 Clinical/regulatory

digi·access - Improve accessibility

Optimize the website for better readability and user experience.

F2 to open

The page is reloaded when used

English

Deutsch

English

Español

Français

Italiano

Nederlands

Polski

Čeština

Türkiye

Dansk

Svenska

Suomi

Português

Norsk

Slovenčina

Magyar

Tiếng Việt

Adjustments for accessibility

Choose your settings

Visually impaired people Support for people with poor eyesight

Off

On

Reading texts aloud Assistance for users who have problems reading online texts

Off

On

Cognitive Restrictions Provides assistance to read and recognise important elements

Off

On

Epileptics Animations are deactivated and dangerous colour combinations reduced

Off

On

ADHD settings Distractions are reduced and a clear focus is set

Off

On

Blind People The screen reader can recognise contents of the web page

Off

On

Motor impaired people The website can be navigated via keyboard

Off

On

Reset all settings Your adjustments for accessibility are set back to the standard settings

Reset

Individual adjustments

Font size

Reset

Line spacing

Reset

Content size

Reset

Word spacing

Reset

Black / white Hide images Highlighting Mouse Simple font

Stop animations Mute sound Reading Mask Magnifier

Extended adjustments

Character spacing

Reset

Highlight link Large pointer

Virtual keyboard Saturation Contrast Video

Background colour

Reset

Text colour

Reset

Link colour

Reset

Title colour

Reset

Close

Reset

Hide widget

Barrierefreie Webseite mit digi·access GmbH, Version 3.47.12 Copyright © 2026

Hide digi·smartPlugin?

Once hidden, it will only be available again by deleting your browser data. Do you want to continue?

Cancel Confirm

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go Cancel

Internet Explorer is not supported

You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser

Accept

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.

OK Cancel

{"analytics":"targeting"}

Disclaimer Image

Disclaimer

Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

Accept

Skip to main content

Select your Market

Global

Global

{{ cartLength }}

DE Change language to German

EN

You are currently browsing content in English

Our share price

€150.9

0.40%

CAREERS

Show All Results

0 matching results. Select 'Show All Results' link to see additional results

Discover with us

2025 Annual Report 2025 Annual Report 2025 Annual Report 2025 Annual Report

FY 2025 Online Report

Annual Report

AI Assistant AI Assistant AI Assistant AI Assistant

Chat with our AI assistant

Get Instant Answers

Build what's next with us. Build what's next with us. Build what's next with us. Build what's next with us.

Build what's next with us.

Explore Careers

Show All Results

0 matching results. Select 'Show All Results' link to see additional results

Discover with us

2025 Annual Report 2025 Annual Report 2025 Annual Report 2025 Annual Report

FY 2025 Online Report

Annual Report

AI Assistant AI Assistant AI Assistant AI Assistant

Chat with our AI assistant

Get Instant Answers

Build what's next with us. Build what's next with us. Build what's next with us. Build what's next with us.

Build what's next with us.

Explore Careers

  • Company

Company

About us

Sustainability

Expertise

Life Science

Healthcare

Electronics

Research

Research

Grants & Awards

Science Space

News & Media

Investors

Investor Relations

Global

DE Change language to German EN You are currently browsing content in English

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function

The company announced today new two-year follow up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with TGCT.

Share Icons revealed to the left

26 Oct 2026 | Darmstadt, Germany

  • Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years

  • Tumor responses remained robust1 and durable2

Not intended for U.K.-, U.S.-, or Canada-based media

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P).

"For people living with TGCT, the impact of the disease is often felt through persistent limitations in mobility, physical function and the ability to carry out everyday activities," said Vinod Ravi, MD, MS, MBA, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, an investigator on the MANEUVER trial. "What is encouraging about these two-year findings is the consistency of improvements, not only in the durability of tumor response, but across the symptoms and functional outcomes that matter to patients. Together with the observed safety profile, these results provide important insight into the potential for pimicotinib to deliver meaningful benefit over time."

The new analysis in patients initially randomized to pimicotinib found that at Week 97, mean changes from baseline were 19.6% in range of motion, -3.9 in stiffness (as measured by the Worst Stiffness Numeric Scale Rating), -3.1 in pain (as measured by the Brief Pain Inventory worst pain rating) and +7.4 in physical function (as measured by the patient-reported PROMIS-PF scale).

Tumor responses also remained robust1 and durable2 through two years. Objective Response Rate (ORR) by blinded independent review committee (BICR) per RECIST v1.1 was 76.2% (95% CI: 63.8, 86.0), remaining unchanged from the one-year analysis, while ORR per BIRC based on tumor volume score (TVS) increased from 74.6% at one year to 77.8% (95% CI: 65.5, 87.3) at two years. Median duration of response was not reached at the time of analysis, and median treatment duration was 22.6 months (range: 1.8-33.6 months) at the March 1, 2026 data cutoff. Fifty-four percent of patients initially randomized to pimicotinib remained on treatment at two years.

In MANEUVER, pimicotinib was well-tolerated, with no evidence of cholestatic hepatotoxicity or hair/skin hypopigmentation. During the randomized, double-blind treatment phase of the trial, treatment-emergent adverse events (TEAEs) leading to treatment discontinuation occurred in one patient (1.6%) treated with pimicotinib; TEAEs leading to dose reduction occurred in 7.9% (n=5) of pimicotinib-treated patients.

"These two-year findings add to the growing body of evidence from the MANEUVER study demonstrating the potential for pimicotinib to meaningfully address some of the burden of TGCT," said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The sustained improvements observed across symptoms, physical function and tumor control reinforce the potential of pimicotinib to address aspects of TGCT that can affect patients every day. These results add to our evolving understanding of the long-term benefit that pimicotinib may provide for people living with this debilitating rare tumor."

TGCT is a rare, locally aggressive tumor occurring in or around the joints leading to progressive worsening of symptoms including pain and reduced mobility of the affected joint, significantly impacting physical function in what is typically an otherwise healthy and young adult population. Patient-reported experiences indicate that up to half of people with TGCT may initially receive an incorrect diagnosis, which can delay appropriate disease management.3 If left untreated or in recurrent cases, TGCT may result in cumulative morbidity and irreversible damage to the bone, joint and surrounding tissues.

Pimicotinib was approved in China by the China National Medical Products Administration (NMPA) in December 2025 and in Canada by Health Canada in June 2026 for the treatment of adult patients with symptomatic TGCT. A regulatory application is currently under review by the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

1 54% ORR as assessed by BIRC based on RECIST v1.1 at week 25 vs. 3% with placebo; p<0.0001. 2 The majority (77%) of patients with response at 25 weeks maintained this clinical benefit after an additional 12 months of treatment. 3 Stern S, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510.

Downloads

  • Merck-Pimicotinib-ESMO-MANEUVER-2-Year-Results-PR-EN.pdf

pdf (159.0 kB)

  • David-Weinreich.png

image/png (3.5 MB)

digi·access - Improve accessibility

Optimize the website for better readability and user experience.

F2 to open

The page is reloaded when used

English

Deutsch

English

Español

Français

Italiano

Nederlands

Polski

Čeština

Türkiye

Dansk

Svenska

Suomi

Português

Norsk

Slovenčina

Magyar

Tiếng Việt

Adjustments for accessibility

Choose your settings

Visually impaired people Support for people with poor eyesight

Off

On

Reading texts aloud Assistance for users who have problems reading online texts

Off

On

Cognitive Restrictions Provides assistance to read and recognise important elements

Off

On

Epileptics Animations are deactivated and dangerous colour combinations reduced

Off

On

ADHD settings Distractions are reduced and a clear focus is set

Off

On

Blind People The screen reader can recognise contents of the web page

Off

On

Motor impaired people The website can be navigated via keyboard

Off

On

Reset all settings Your adjustments for accessibility are set back to the standard settings

Reset

Individual adjustments

Font size

Reset

Line spacing

Reset

Content size

Reset

Word spacing

Reset

Black / white Hide images Highlighting Mouse Simple font

Stop animations Mute sound Reading Mask Magnifier

Extended adjustments

Character spacing

Reset

Highlight link Large pointer

Virtual keyboard Saturation Contrast Video

Background colour

Reset

Text colour

Reset

Link colour

Reset

Title colour

Reset

Close

Reset

Hide widget

Barrierefreie Webseite mit digi·access GmbH, Version 3.47.12 Copyright © 2026

Hide digi·smartPlugin?

Once hidden, it will only be available again by deleting your browser data. Do you want to continue?

Cancel Confirm

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go Cancel

Internet Explorer is not supported

You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser

Accept

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.

OK Cancel

{"analytics":"targeting"}

Disclaimer Image

Disclaimer

Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

Accept

Skip to main content

Select your Market

Global

Global

{{ cartLength }}

DE Change language to German

EN

You are currently browsing content in English

Our share price

€150.9

0.40%

CAREERS

Show All Results

0 matching results. Select 'Show All Results' link to see additional results

Discover with us

2025 Annual Report 2025 Annual Report 2025 Annual Report 2025 Annual Report

FY 2025 Online Report

Annual Report

AI Assistant AI Assistant AI Assistant AI Assistant

Chat with our AI assistant

Get Instant Answers

Build what's next with us. Build what's next with us. Build what's next with us. Build what's next with us.

Build what's next with us.

Explore Careers

Show All Results

0 matching results. Select 'Show All Results' link to see additional results

Discover with us

2025 Annual Report 2025 Annual Report 2025 Annual Report 2025 Annual Report

FY 2025 Online Report

Annual Report

AI Assistant AI Assistant AI Assistant AI Assistant

Chat with our AI assistant

Get Instant Answers

Build what's next with us. Build what's next with us. Build what's next with us. Build what's next with us.

Build what's next with us.

Explore Careers

  • Company

Company

About us

Sustainability

Expertise

Life Science

Healthcare

Electronics

Research

Research

Grants & Awards

Science Space

News & Media

Investors

Investor Relations

Global

DE Change language to German EN You are currently browsing content in English

Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors

Collaboration between Merck, NVIDIA, Microsoft and Dawn Health to explore how AI-facilitated technology can help build an innovative model for PSPs.

Share Icons revealed to the left

21 Oct 2026 | Darmstadt, Germany

  • Collaboration to explore how AI-facilitated technology can help make patient support programs more individualized, responsive and continuously available to people living with rare tumors

  • Collaboration brings together clinical and pharmaceutical expertise, digital health product development, and enterprise AI services

  • Merck aims to bring the model to patients with desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN)

Merck, a leading science and technology company, today announced a collaboration with NVIDIA Corporation (Santa Clara, California, USA), Microsoft Corporation (Redmond, Washington, USA) and Dawn Health A/S (Copenhagen, Denmark) to build an innovative model for Patient Support Programs (PSPs). The four-way collaboration brings together pharmaceutical and clinical expertise, enterprise technology, AI services and digital health product design, with the shared goal of making specialist-level support more individualized, responsive and continuously available to patients, no matter how complex their treatment journey is.

“Across their treatment journeys, patients with rare tumors often describe challenges that extend well beyond clinical care, like navigating multiple specialists, complex regimens and repeatedly reconstructing their treatment story for each new stakeholder. Our integrated support ecosystem starts with the need. The goal is to truly transform how healthcare is experienced, not add another tool on top of it,” said Miguel Fernández Alcalde, Head of Global Commercial Strategy for Healthcare business sector of Merck. “This solution is designed to make more continuous and personalized support available across small and geographically dispersed rare tumor populations, including patients who may have limited access to specialist care.”

Merck is collaborating on the design of a pioneering integrated support ecosystem tailored to individual needs of people living with rare tumors, their disease state and circumstances. In practice, the outcome is a AI-facilitated companion, available to patients 24/7. Every interaction is grounded in clinically reviewed content, with defined escalation pathways, and full traceability and audit capabilities. Designed to complement, not replace, the care patients receive from their healthcare team, the companion extends the reach and responsiveness of support, while a nurse or healthcare provider remains available when needed. The collaboration builds on and expands a previously announced partnership between Merck and Dawn Health to support rare tumor patients.

Once technical feasibility is confirmed and regulatory requirements are met, the new model will be piloted in key markets in Europe with an initial focus on rare tumors, specifically desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN). These disease areas are known to have complex treatment pathways, and high unmet needs of patients, which makes the case for more consistent, higher-quality support particularly urgent.

The multi-way collaboration is grounded on a shared belief that bringing digital interactions, human services and structured data closer together could, over time, help build a more complete view of how a patient's needs evolve throughout their journey.

Three other relevant players in the technology space have key roles in developing this novel patient solution. NVIDIA contributes AI technology & services including NVIDIA Nemotron, NVIDIA Nemotron Reranking open model, NVIDIA NeMo Guardrails, NeMo Relay, NeMo Gym, NeMo Evaluator, NeMo Data Designer, to help power the program's performance and safety capabilities; Microsoft provides cloud services (Microsoft Foundry, Azure AI Search, the AI Red Teaming Agent as well as Azure Kubernetes Service, Azure SQL and Azure Monitor to run the Dawn Platform); and Dawn Health leads product development, regulatory experience, and the design of patient-facing applications based on the Dawn Platform offering.

Traditional PSPs have long been a cornerstone of the support pharmaceutical companies offer patients, providing structured, validated guidance throughout the treatment journey. As treatment and care pathways grow more complex, patient demand for support is rising, while the reach of these programs often cannot keep pace. Patients in small or dispersed populations, such as those with rare tumors, continue to have limited access to specialist care.

Downloads

  • 4wayCollab-Press-Release-21-10-26-EN.pdf

pdf (121.1 kB)

  • Miguel-Fernandez-Alcalde.jpg

image/jpeg (53.9 kB)

Prompts

MERCK Kommanditgesellschaft auf Aktien (ticker MRK), listed in Germany.

ETFs Holding MERCK Kommanditgesellschaft auf Aktien

ETF Weight in ETF Shares Market value As of
BKCI 4.09% 32,561 $ 5.375M Jul 31, 2026
FEOE 2.42% 285,429 $ 46.084M Aug 31, 2026
FEGE 1.55% 240,733 $ 38.868M Aug 31, 2026
DSTX 1.29% 3,611 $ 606.265K Jun 30, 2026
MFSI 1.21% 91,699 $ 14.805M Aug 31, 2026
FPAG 1.16% 37,196 $ 6.241M Jun 30, 2026
RCGE 0.52% 3,068 $ 510K Nov 18, 2026
GEW 0.23% 2,030 $ 327.754K Aug 31, 2026
RINT 0.22% 1,838 $ 308.399K Jun 30, 2026
GMOI 0.18% 7,719 $ 1.246M Aug 31, 2026
DFIV 0.11% 153,343 $ 25.141M Nov 12, 2026
NTSI 0.09% 2,618 $ 439.545K Jun 30, 2026
DFAI 0.06% 70,567 $ 11.569M Nov 12, 2026
AVDE 0.06% 67,461 $ 11.034M Nov 16, 2026
DFSI 0.05% 3,614 $ 592.515K Nov 12, 2026
AVSD 0.05% 1,073 $ 175.504K Nov 16, 2026
JSTC 0.02% 399 $ 65.739K Nov 17, 2026
DFIC 0.02% 18,367 $ 3.011M Nov 12, 2026
DXIV 0.02% 285 $ 46.726K Nov 12, 2026
DFAX 0.02% 11,883 $ 1.948M Nov 12, 2026